Johnson & Johnson (NYSE:JNJ) Price Target Raised to $221.00 at Bank of America

Johnson & Johnson (NYSE:JNJ) had its target price boosted by Bank of America from $220.00 to $221.00 in a research report sent to investors on Thursday morning,Benzinga reports. The brokerage currently has a neutral rating on the stock.

JNJ has been the subject of several other reports. Guggenheim upped their price objective on shares of Johnson & Johnson from $206.00 to $227.00 and gave the stock a “buy” rating in a report on Friday, December 5th. TD Cowen upped their price target on shares of Johnson & Johnson from $222.00 to $250.00 and gave the company a “buy” rating in a report on Thursday. Morgan Stanley raised their price target on Johnson & Johnson from $197.00 to $200.00 and gave the company an “equal weight” rating in a research report on Thursday. Johnson Rice set a $190.00 price objective on Johnson & Johnson and gave the stock a “hold” rating in a research report on Wednesday, October 22nd. Finally, Barclays increased their target price on Johnson & Johnson from $197.00 to $217.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 30th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $219.86.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $218.58 on Thursday. The stock has a market capitalization of $526.62 billion, a P/E ratio of 19.78, a P/E/G ratio of 2.24 and a beta of 0.34. The business has a 50-day moving average of $207.86 and a two-hundred day moving average of $188.48. Johnson & Johnson has a fifty-two week low of $141.50 and a fifty-two week high of $222.17. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 21st. The company reported $2.46 earnings per share for the quarter, hitting the consensus estimate of $2.46. The firm had revenue of $24.56 billion during the quarter, compared to analyst estimates of $24.14 billion. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The company’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same period in the previous year, the company earned $2.04 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. On average, equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be paid a dividend of $1.30 per share. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a yield of 2.4%. Johnson & Johnson’s payout ratio is currently 50.19%.

Hedge Funds Weigh In On Johnson & Johnson

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vista Investment Partners II LLC boosted its stake in Johnson & Johnson by 1.2% in the 4th quarter. Vista Investment Partners II LLC now owns 3,811 shares of the company’s stock valued at $789,000 after buying an additional 47 shares in the last quarter. Campbell Deegan Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 1.6% during the fourth quarter. Campbell Deegan Wealth Management LLC now owns 2,990 shares of the company’s stock valued at $619,000 after acquiring an additional 48 shares during the period. Centennial Wealth Advisory LLC boosted its stake in shares of Johnson & Johnson by 2.2% in the 4th quarter. Centennial Wealth Advisory LLC now owns 2,284 shares of the company’s stock valued at $473,000 after purchasing an additional 49 shares in the last quarter. Gleason Group Inc. grew its holdings in shares of Johnson & Johnson by 0.8% in the 4th quarter. Gleason Group Inc. now owns 6,390 shares of the company’s stock worth $1,322,000 after purchasing an additional 50 shares during the last quarter. Finally, ACT Wealth Management LLC increased its position in shares of Johnson & Johnson by 3.9% during the 4th quarter. ACT Wealth Management LLC now owns 1,399 shares of the company’s stock worth $290,000 after purchasing an additional 52 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Q4 print and 2026 outlook: J&J beat revenue expectations, reported stronger margins and gave FY2026 sales and EPS guidance that was modestly above consensus — the core drivers cited were oncology strength and MedTech momentum. This underpins the bullish analyst reaction and higher expectations for organic growth. Business Wire: Q4 and Full-Year 2025 results
• Positive Sentiment: Large analyst upgrade: Scotiabank boosted its price target sharply to $265 (sector outperform), signaling meaningful upside versus the current level and likely supporting buying interest. The Fly: Scotiabank price-target raise
• Positive Sentiment: Technical/market momentum: MarketBeat highlights a trend-following buy signal after the pullback to support levels, which can attract momentum traders and reduce downside risk for buyers. MarketBeat: trend-following buy signal
• Neutral Sentiment: Analyst tweaks with limited conviction: Bank of America and Stifel nudged targets higher (to $221 and $220 respectively) but kept neutral/hold stances — these adjustments offer modest upside but little change to conviction. Benzinga: analyst target changes
• Positive Sentiment: Dividend and longer-term thesis remain intact: Coverage pieces note J&J’s status as a Dividend King with a sustainable payout and a growing MedTech pipeline (including OTTAVA robotics), supporting steady institutional demand. Zacks: dividend thesis
• Negative Sentiment: Talc litigation moving forward: A court ruling will allow plaintiffs’ expert testimony in the talc MDL, increasing legal uncertainty and potential exposure that remains an overhang for the stock. Benzinga: talc litigation update
• Negative Sentiment: Stelara biosimilar pressure: Investors remain cautious after Stelara sales fell sharply following patent loss; biosimilar competition is dragging growth in that franchise and was cited as a reason for pre-market weakness even after the beat. Blockonomi: Stelara and market reaction

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.